These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4187027)

  • 41. [Action of desoxyfructo-serotonin on Mycobacterium leprae. Results of inoculation of human biopsy specimens in the mouse after a year of treatment].
    Ferracci C; Baquillon G; Pattyn SR
    Acta Leprol; 1983; 1(4):233-5. PubMed ID: 6377799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clarithromycin is bactericidal against strains of Mycobacterium leprae resistant and susceptible to dapsone and rifampin.
    Walker LL; Van Landingham RM; Shinnick TM
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):59-65. PubMed ID: 8326182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persister M. leprae after introductory rifampicin followed by dapsone therapy.
    Sreevatsa ; Girdhar BK; Desikan KV
    Lepr India; 1981 Jul; 53(3):350-3. PubMed ID: 7278139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secondary dapsone-resistant leprosy in Shanghai Municipality.
    Ji BH; Chen JK; Zhang JL; Hou YH; Ni GX; Zhang RB
    Lepr Rev; 1983 Sep; 54(3):197-202. PubMed ID: 6355724
    [No Abstract]   [Full Text] [Related]  

  • 46. Correlation viability/morphology in Mycobacterium leprae.
    Silva MT; Macedo PM; Portaels F; Pattyn SR
    Acta Leprol; 1984; 2(2-4):281-91. PubMed ID: 6398588
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccination with DNA of the Mycobacterium tuberculosis 85B antigen protects mouse foot pad against infection with M. leprae.
    Roche PW; Neupane KD; Failbus SS; Kamath A; Britton WJ
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2):93-8. PubMed ID: 11757171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro cultivation of an acid-fast nocardioform chemoautotroph from mouse footpad-passaged strain of leprosy bacillus.
    Chakrabarty AN; Dastidar SG
    Indian J Exp Biol; 1987 May; 25(5):302-4. PubMed ID: 2444533
    [No Abstract]   [Full Text] [Related]  

  • 49. Increase in prevalence of leprosy caused by dapsone-resistant Mycobacterium leprae.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1982 Jan; 30(52):637-8. PubMed ID: 6798411
    [No Abstract]   [Full Text] [Related]  

  • 50. Assessment of viability by normal mouse foot-pad and bacillary ATP bioluminescence assay in multibacillary cases treated with an MDT regimen using conventional as well as newer drugs like minocycline and ofloxacin.
    Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
    Indian J Lepr; 2000; 72(4):437-42. PubMed ID: 11212477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined rifampin and dapsone chemotherapy of Mycobacterium leprae infection of the neonatally thymectomized Lewis rat.
    Fieldsteel AH; Levy L
    Int J Lepr Other Mycobact Dis; 1980 Sep; 48(3):267-76. PubMed ID: 7002811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dapsone resistance in leprosy.
    Browne SG
    Trans St Johns Hosp Dermatol Soc; 1973; 59(2):225-9. PubMed ID: 4602407
    [No Abstract]   [Full Text] [Related]  

  • 53. [Transmission of Mycobacterium leprae into mouse foot-pads. 1. Results with a wild strain in Japan].
    Matsuo Y; Nakusa Y
    Nihon Saikingaku Zasshi; 1967 Aug; 22(8):482-9. PubMed ID: 4867766
    [No Abstract]   [Full Text] [Related]  

  • 54. Dosage and site of entry influence growth and dissemination of Mycobacterium leprae in T900r mice.
    Ebenezer GJ; Arumugam S; Job CK
    Int J Lepr Other Mycobact Dis; 2002 Dec; 70(4):245-9. PubMed ID: 12768925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent advances in the study of the leprosy bacillus.
    Rees RJ
    Sci Basis Med Annu Rev; 1969; ():320-35. PubMed ID: 4917843
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of purification and fluorescent staining on viability of Mycobacterium leprae.
    Lahiri R; Randhawa B; Krahenbuhl JL
    Int J Lepr Other Mycobact Dis; 2005 Sep; 73(3):194-202. PubMed ID: 16830641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dapsone-resistant Mycobacterium leprae in a patient receiving dapsone in low doses.
    Browne SG
    Int J Lepr Other Mycobact Dis; 1969; 37(3):296-301. PubMed ID: 4906048
    [No Abstract]   [Full Text] [Related]  

  • 58. Mast cell and Mycobacterium leprae in experimental leprosy.
    Kumar R; Vaidya MC
    Hansenol Int; 1982 Jun; 7(1):1-7. PubMed ID: 6764919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lepra reaction. Its relation with fragmentation of Mycobacterium leprae under sulfone therapy.
    Saul A; Segura N
    Int J Lepr Other Mycobact Dis; 1966; 34(1):17-22. PubMed ID: 5327411
    [No Abstract]   [Full Text] [Related]  

  • 60. Prevalence survey of secondary dapsone resistance in leprosy in Kancheepuram and Tiruvannamalai control units of Tamil Nadu.
    Neelan PN; Noordeen SK; Balakrishnan S; Pandian PR
    Lepr India; 1983 Apr; 55(2):222-30. PubMed ID: 6355650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.